Is Bruker Corporation (BRKR) Overvalued?
We dive into why Bruker Corporation (BRKR) could be considered overvalued on 2026-07-23, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
Commentary & Analysis
Why Bruker Corporation’s (BRKR) Stock Is Up 6.55%
As of Tuesday, July 21, Bruker Corporation’s BRKR share price has surged by 6.55%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Bruker Corporation’s (BRKR) Stock Is Up 5.55%
As of Thursday, July 09, Bruker Corporation’s BRKR share price has surged by 5.55%, which has investors questioning if this is right time to sell.Michael Rose
Which Is a Better Investment, AbCellera Biologics Inc. or Bruker Corporation Stock?
Learn more about whether AbCellera Biologics Inc. or Bruker Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why Bruker Corporation’s (BRKR) Stock Is Up 5.62%
As of Thursday, June 25, Bruker Corporation’s BRKR share price has surged by 5.62%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | BRKR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9,565.9 | $1,790.4 | 77% |
|
| Shares Out (Mil) | 152.7 | 94.8 | 71% |
|
| Institutional Ownership | 74.3% | 90.0% | 45% |
|
| Float (Mil) | 103.6 | 69.9 | 62% |
|
| Beta | 1.30 | 1.20 | 75% |
|
| Avg Daily Volume (000s) | 1,967 | 814 | 82% |
|
| Price Change (52-week) |
53.7% | 80.2% | 81% |
|
| Growth | BRKR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.6% | 7.8% | 64% |
|
| Net Income (5yr) | (15.5%) | (13.7%) | 25% |
|
| EPS (5yr) | (16.5%) | 0.7% | 16 |
|
| Dividends (5yr) | 4.6% | 0.0% | 60% |
|
| Cash Flow (5yr) | 107.5% | (15.0%) | 99% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 13 | |
| Current EPS | $0.384 | $2.120 | $2.429 | |
| Month Ago EPS | $0.383 | $2.117 | $2.436 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | $0.458 | $2.115 | $2.413 | |
| Year/Year Chg | 1,820% | (1,513%) | (1,977%) | |
| Financials | BRKR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,459 | $785 | 69% |
|
| Net Income (TTM) (Mil) | ($12) | ($14) | 28% |
|
| EPS (TTM) | ($0.240) | ($0.200) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | $140 | $53 | 55% |
|
| Net Cash Flow (TTM) (Mil) | ($50) | ($4) | 19% |
|
| Long-Term Debt (Q1) (Mil) | $1,663 | $270 | 72% |
|
| Enterprise Value (Q1) (Mil) | $10,246 | $2,444 | 74% |
|
| Valuation | BRKR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.91 | 2.92 | 72% |
|
| P/E | na | 43.7 | na |
|
| Dividend Yield | 0.3% | 0.0% | 61% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | BRKR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.6% | 47.6% | 60% |
|
| Net Margin | (0.3%) | (2.9%) | 31% |
|
| ROA | (0.2%) | (2.8%) | 38% |
|
| ROE | (0.5%) | (4.5%) | 35% |
|
| Liabilities to Assets | 59.2% | 43.0% | 53% |
|
| F-Score | 4 | 5 | 34% |
|
Bruker Corporation did not pass any screens on 7/31/2026.
